Patents Examined by Chris Simmons
  • Patent number: 9006226
    Abstract: The present invention relates to dihydropteridinones, their use as modulators of ?-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with ?-secretase and/or its substrate and therefore modulate the formation of A? peptides.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: April 14, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kai Gerlach, Christian Eickmeier, Claudia Heine, Niklas Heine, Alexander Weber
  • Patent number: 8992891
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. More particularly, the invention relates to combined therapies for treating said disease by affecting PMP22 expression in a subject.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: March 31, 2015
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • Patent number: 8980914
    Abstract: This therapeutic agent for chronic obstructive pulmonary disease comprises, an active ingredient, at least one of a 7-aminoquinolinone derivative represented by the general formula (I): wherein R1 represents a hydrogen atom or an alkyl group; R2 and R3 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group and an alkenyl group; and R4 and R5 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group, an alkenyl group and an aralkyl group, and its physiologically acceptable salt.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: March 17, 2015
    Assignee: Mariposa Health Limited
    Inventors: Hidetsugu Takagaki, Yasuo Aoki, Mitsuteru Ishiwara, Nobuaki Mizutani
  • Patent number: 8962616
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: February 24, 2015
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Elizabeth Mary Beck, Jennifer Elizabeth Davoren, Brian Thomas O'Neill
  • Patent number: 8940718
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: January 27, 2015
    Assignee: Gilead Pharmasset LLC
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila Zipfel
  • Patent number: 8921341
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: December 30, 2014
    Assignee: Gilead Pharmasset LLC
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, Ashley Anne Katana, Darryl Kato, Evan S. Krygowski, John O. Link, James Taylor, Chinh Viet Tran, Teresa Alejandra Trejo Martin, Zheng-Yu Yang, Sheila Zipfel
  • Patent number: 8828363
    Abstract: An aqueous based pharmaceutical composition for use as a oral hygienic treatment is described. The composition contains a pharmaceutically effective amount of a tetracycline-based antibiotic; a water-soluble calcium salt that aids in solubilizing the tetracycline-based antibiotic; a thickener; a pH adjustment agent; an antifoaming agent; an excipient; a surfactant; a preservative; and a flavoring agent. A method of making the aqueous based pharmaceutical composition includes the steps of adjusting, defoaming, dispensing, dispersing, dissolving, flavoring, heating, minimizing, pouring, solubilizing, suspending, and sweetening. A method of using the aqueous based pharmaceutical composition is also disclosed which includes the steps of expectorating, gargling, obtaining, pouring, receiving, and swishing.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: September 9, 2014
    Inventor: Gary H. Eirew
  • Patent number: 8821848
    Abstract: A composition and method useful in promoting hemostasis, absorbing ooze, and being antimicrobial with respect to an open wound. The composition broadly includes an antimicrobial agent, preferably povidone iodine, preferably a ferrate compound, and a cation ion exchange resin. This composition will destroy a biofilm which has formed over the open wound in providing a soluble iron compound, a cation chelation compound, and an active antimicrobial compound effective against planktonic microorganisms and biofilms. The antimicrobial agent is locked or sealed within the scab formed over the wound to maintain long-term positioning and anti-dilution of the antimicrobial over the wound.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: September 2, 2014
    Assignee: Biolife, L.L.C.
    Inventors: Talmadge Kelly Keene, John Hen
  • Patent number: 8759349
    Abstract: The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: June 24, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Sara Frattini, Dieter Hamprecht, Joerg Kley
  • Patent number: 8741958
    Abstract: The present application provides a synthetic spilanthol flavor composition that includes (2E,6Z,8E)-N-(2-methylpropyl)-2,6,8-decatrienamide. The synthetic spilanthol composition can also contain, and at least one of (2E,6E,8E)-N-(2-methylpropyl)-2,6,8-decatrienamide and (2E,6Z,8Z)-N-(2-methylpropyl)-2,6,8-decatrienamide, the (N-(2-methylpropyl)-2,6,8-decatrienamide being present in amounts effective to impart a salivating or tingle effect while reducing the perception of off notes, as compared to the off-notes perceived upon consumption of natural spilanthol (e.g. spilanthol obtained from jambu oleoresin). Methods of increasing salivation and/or providing a tingling sensation upon consuming an orally consumable product that include adding to the product a synthetic spilanthol flavor composition are also provided.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: June 3, 2014
    Assignee: Takasago International Corporation
    Inventors: Louis Lombardo, Michael E. Lankin, Kenya Ishida, Shigeru Tanaka, Hideo Ujihara, Kenji Yagi, Jennifer B. Mei, Carter B. Green, Amrit S. Mankoo
  • Patent number: 8735428
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 27, 2014
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: 8722705
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: May 13, 2014
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: 8722647
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: May 13, 2014
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: 8673322
    Abstract: Disclosed is a process for the preparation of laquinimod sodium which removes the impurities after the salt formation step, thus resulting in crystals of higher purity as well as crystals having improved crystalline characteristics.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: March 18, 2014
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anton Frenkel, Eduard Gurevich, Avital Laxer
  • Patent number: 8673939
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: March 18, 2014
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: 8669282
    Abstract: The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: March 11, 2014
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Steven C. Zicker, Nolan Zebulon Frantz
  • Patent number: 8668902
    Abstract: In a personal care daily practice, common human malodor in breath can be treated and eliminated or substantially reduced through the use of a treatment comestible, lozenge, chewing gum or scraper prepared by combining a hardenable natural or artificial sweetener or gum base with an amount of activated carbon effective in reducing such malodors.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: March 11, 2014
    Assignee: Vapor Shield, Inc.
    Inventor: David M. Phillips
  • Patent number: 8652444
    Abstract: Antiplaque oral compositions are provided that contain an orally acceptable carrier and an antibacterial effective amount of the compound of formula (I). In various embodiments, the compositions contain from about 0.001% to about 10% by weight of the compound of formula (I).
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: February 18, 2014
    Assignee: Colgate-Palmolive Company
    Inventors: Ravi Subramanyam, Prem Sreenivasan
  • Patent number: 8647646
    Abstract: Disclosed is a process for the preparation of laguinimod sodium which removes the impurities after the salt formation step, thus resulting in crystals of higher purity as well as crystals having improved crystalline characteristics.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: February 11, 2014
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anton Frenkel, Eduard Gurevich, Avital Laxer
  • Patent number: 8648095
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: February 11, 2014
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis